🇺🇸 FDA

Company profile · Sponsor

Mabxience

Mabxience Research SL

E60900A · EMA pharma Madrid, ES
Pipeline
4
Drugs
0
Patents
0

Quick answer

Mabxience (E60900A) is a pharma company. headquartered in Madrid, ES. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E60900A
Exchange EMA
Company type pharma
Headquarters Madrid, ES

Pipeline (4)

Search pipeline →

  1. A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer

    Mabxience

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  2. Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe

    Mabxience

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  3. OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., US Opdivo

    Mabxience

    Previously Untreated Advanced (Unresectable or Metastatic) Melanoma

    phase 3 small molecule active

    1 trial

  4. A RANDOMIZED, DOUBLE-BLIND, THREE-PART, TWO-PERIOD, TWO-SEQUENCE, SINGLE-DOSE, CROSS-OVER STUDY TO COMPARE THE PHARMACOKINETICS (PK), SAFETY AND IMMUNOGENICITY PROFILE OF MB04 (PROPOSED ETANERCEPT BIOSIMILAR), EU-SOURCED ENBREL® AND US-LICENSED ENBREL® IN HEALTHY MALE VOLUNTEERS.

    Mabxience

    Not applicable, Healthy Volunteers

    phase 1 other active

    1 trial

Frequently asked questions

What is Mabxience?

Mabxience (E60900A) is a pharma company. headquartered in Madrid, ES. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Mabxience sponsor?

We track 4 ClinicalTrials.gov-linked programs for Mabxience, including A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer and 3 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Mabxience company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.